Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance

Advanced Drug Delivery Reviews

Volumn 59, Issue 9-10, 2007, Pages 1054-1068

  Clairambault, Jean ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Cancer drug toxicity; Chronotherapy; Drug delivery optimization; Pharmacokinetics pharmacodynamics; Theoretical models; Treatment outcome

Indexed keywords

BIOACTIVITY; CELLS; CYTOTOXICITY; METABOLISM; OPTIMIZATION; PARAMETER ESTIMATION; PHARMACOKINETICS;

CANCER DRUG TOXICITY; CHRONOTHERAPY; CIRCADIAN PERIODIC DRUG DYNAMICS; DRUG METABOLISM;

DRUG DELIVERY;

OXALIPLATIN;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CELL POPULATION; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; COMPUTER SIMULATION; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; INTESTINE CELL; JEJUNUM MUCOSA; LEUKOPENIA; MUCOSAL NECROSIS; NEUROTOXICITY; NONHUMAN; OSTEOSARCOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; THEORETICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CIRCADIAN RHYTHM; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG SYNERGISM; ENTEROCYTES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 35148831322     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.08.004     Document Type: Review

References (45)

1. Goldbeter A. A model for circadian oscillations in the Drosophila period protein (PER). Proc. R. Soc. Lond. B 261 (1995) 319-324
2. Goldbeter A. Computational approaches to cellular rhythms. Nature 420 (2002) 238-245
3. Leloup J.-C., and Goldbeter A. Toward a detailed computational model of the mammalian circadian clock. Proc. Nat. Acad. Sci. 100 12 (2003) 7051-7056
4. Fu L., Pelicano H., Liu J., Huang P., and Lee C.C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 (2002) 41-50
5. Rosbash M., and Takahashi J. The cancer connection. Nature 420 (2002) 373-374
6. Fu L., and Lee C.C. The circadian clock: pacemaker and tumor suppressor. Nature Reviews 3 (2003) 351-361
7. Lévi F. Cancer chronotherapeutics. Special Issue of Chronobiology International 19 (1) (2002)
8. Hecquet B. Modélisation pour une chronopharmacologie. Pathologie-Biologie 35 6 (1986) 937-941
9. Clairambault J., Claude D., Filipski E., Granda T., and Lévi F. Toxicité et efficacité antitumorale de l'oxaliplatine sur l'ostéosarcome de Glasgow induit chez la souris: un modèle mathématique. Pathologie-Biologie 51 (2003) 212-215
10. Lévi F., Perpoint B., et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer 29A 9 (1993) 1280-1284
11. Granda T.G., D'Attino R.M., Filipski E., et al. Circadian optimization of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Brit. J. Cancer 86 (2002) 999-1005
12. Boughattas N.A., Lévi F., et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxaloplatinum(II) in mice. Cancer Research 49 (1989) 3362-3368
13. Haurie C., Dale D.C., and Mackey M.C. Cyclical neutropenia and other hematological disorders: a review of mechanisms and mathematical models. Blood 92 8 (1998) 2629-2640
14. Lévi F., Metzger G., Massari C., and Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38 (2000) 1-21
15. Faivre S., Chan D., Salinas R., Woynarowska B., and Woynarowski J.M. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochemical pharmacology 66 (2003) 225-237
16. Chaney S.G., Campbell S.L., Bassett E., and Wu Y.B. Recognition and processing of cisplatin-and oxaliplatin-DNA adducts. Clin. Rev. Oncol. Hematol. 53 (2005) 3-11
17. Kweekel D.M., Gelderblom H., and Guchelaar H.-J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Canc. Treatment Rev. 31 (2005) 90-105
18. Wang D., and Lippard S.L. Cellular processing of platinum anticancer drugs. Nature Rev. Drug Discovery 4 (2005) 307-320
19. Mishima M., Samimi G., Kondo A., Lin X., and Howell S.B. The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer 38 (2002) 1405-1412
20. Boughattas N.A., Hecquet B., Fournier C., Bruguerolle B., Trabelsi A., Bouzouita K., Omrane B., and Lévi F. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time. Biopharm Drug Dispos. 15 (1994) 761-773
21. Potten C.S., and Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons Crypt. Dev. 110 (1990) 1001-1020
22. Wright N., and Alison M. The Biology of Epithelial Cell Populations vol.2 (1984), Clarendon Press, Oxford 842-869 chap.23
23. Edelstein-Keshet L. Mathematical Models in Biology (1988), McGraw-Hill, New York 210-270
24. Gyllenberg M., and Webb G.F. Quiescence as an explanation of Gompertzian tumor growth. Growth, Development and Aging 53 (1989) 25-33
25. Gyllenberg M., and Webb G.F. A nonlinear structured population model of tumor growth with quiescence. J. Math. Biol. 28 (1990) 671-694
26. Jackson T.L., and Byrne H.M. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math. Biosci. 164 (2000) 17-38
27. Sherratt J.A., and Chaplain M.A.J. A new mathematical model for avascular tumour growth. J. Math. Biol. 43 (2001) 291-312
28. Hahnfeldt P., Panigrahy D., Folkman J., and Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Research 59 (1999) 4770-4775
29. Ergun A., Camphausen K., and Wein L.M. Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 65 (2003) 407-424
30. Goldie J.H., and Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63 (1979) 1727-1733
31. Britton N.F., Wright N.A., and Murray J.D. A mathematical model for cell population kinetics in the intestine. J. Theor. Biol. 98 (1982) 531-541
32. Li X.M., Metzger G., Filipski E., Lemaigre G., and Lévi F. Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in mice. Arch. Toxicol. 72 (1998) 574-579
33. Hastings M.H., Reddy A.B., and Maywood E.S. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat. Rev./Neurosci. 4 (2003) 649-661
34. Perko L. Differential Equations and Dynamical Systems. 2nd edition (1996), Springer 119-129
35. Scheving L.E., Burns E.R., Pauly J.E., and Tsai T.H. Circadian variations in cell division of the mouse alimentary tract, bone marrow and corneal epithelium. Anat. Rec. 191 (1978) 479-486
36. Iliadis A., and Barbolosi D. Optimising drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Computers Biomed. Res. 33 (2000) 211-226
37. Iliadis A., and Barbolosi D. Optimising drug regimens in cancer chemotherapy: a simulation study using a PK-PD model. Computers Biol. Med. 31 (2001) 157-172
38. Basdevant C., Clairambault J., and Lévi F. Optimisation of time-scheduled regimen for anti-cancer drug infusion. Math. Model. Numer. Anal. 39 6 (2005) 1069-1086
39. Forger D.B., and Kronauer R.E. Reconciling mathematical models of biological clocks by averaging on approximate manifolds. SIAM J. Appl. Math. 62 4 (2002) 1281-1296
40. Levi F.A., Tubiana-Mathieu N., Focan C., Brézault-Bonnet C., Coudert B., Carvalho C., Genet D., Giacchetti S., Lentz M.-A., and Baron B. First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL410) versus 2-day FOLFOX2. A Multicenter Randomized Phase III Trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963). ASCO Meeting Abstracts 22 (2004) 3526
41. Panetta J.C. A mathematical model of drug resistance: heterogeneous tumors. Math. Biosci. 147 (1998) 41-61
42. Kozusko F., Chen P.H., Grant S.G., Day B.W., and Panetta J.C. A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math. Biosci. 170 (2001) 1-16
43. Clairambault J., Michel P., and Perthame B. Circadian rhythm and tumour growth. C. R. Acad. Sci. (Paris) 342 1 (2006) 17-22
44. Panetta J.C. A mathematical model of breast and ovarian cancer treated with Paclitaxel. Math. Biosci. (1997) 89-113
45. Boldrini J.L., and Costa M.I.S. Therapy burden, drug resistance, and optimal treatment regimen for cancer therapy. IMA J. Math. Appl. Med. Biol. 17 (2000) 33-51